PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
29.77%
Some net income increase while TRVN is negative at -108.20%. John Neff would see a short-term edge over the struggling competitor.
-0.50%
Negative yoy D&A while TRVN is 177.38%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
15.92%
Lower deferred tax growth vs. TRVN's 88.12%, implying fewer future tax liabilities. David Dodd would confirm there’s no short-term tax shock instead.
0.65%
Less SBC growth vs. TRVN's 6.39%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
-31.26%
Negative yoy working capital usage while TRVN is 302.49%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.84%
Lower AP growth vs. TRVN's 161.62%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-40.45%
Negative yoy usage while TRVN is 217.27%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-15.92%
Negative yoy while TRVN is 1520.25%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
32.67%
Operating cash flow growth similar to TRVN's 32.95%. Walter Schloss would see parallel improvements or market conditions in cash generation.
100.00%
CapEx growth of 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while TRVN is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
-58.30%
Negative yoy issuance while TRVN is 299.90%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.